Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Completed 8Active not recruiting 3Terminated 1Recruiting 1No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 29Breast Neoplasms 17Neoplasms 14Neoplasm Metastasis 10Ovarian Neoplasms 9Carcinoma, Renal Cell 8Melanoma 7Leukemia, Lymphocytic, Chronic, B-Cell 7Colorectal Neoplasms 7Urinary Bladder Neoplasms 6Small Cell Lung Carcinoma 6Recurrence 6Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Thyroid Neoplasms 5Thyroid Cancer, Papillary 5Prostatic Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Pancreatic Neoplasms 5Lung Neoplasms 5Hematologic Neoplasms 5Head and Neck Neoplasms 5Endometrial Neoplasms 5Colonic Neoplasms 5Lymphoma 4Leukemia, Myeloid, Acute 4Urothelial Cancer 3Stomach Neoplasms 3Sarcoma 3Salivary Gland Neoplasms 3

Interventions

venetoclax 1obinutuzumab 1ivosidenib 1acalabrutinib 1Midazolam 1Itraconazole 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Has announcements × Leukemia × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03173248 2025-11-10

AGILE

Servier

Phase 3 Active not recruiting
146 enrolled 11 charts 1 FDA
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT03836261 2024-12-27

AMPLIFY

Acerta Pharma BV

Phase 3 Active not recruiting
984 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡